{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:39:01Z","timestamp":1786981141697,"version":"build-2736575974"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T00:00:00Z","timestamp":1674777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T00:00:00Z","timestamp":1674777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s10787-023-01138-8","type":"journal-article","created":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T15:32:37Z","timestamp":1674833557000},"page":"787-797","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["High-dose intravenous anakinra treatment is safe and effective in severe and critical COVID-19 patients: a propensity score-matched study in a single center"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1788-3837","authenticated-orcid":false,"given":"Murat","family":"Bekta\u015f","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Servet","family":"Y\u00fcce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Ay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammed Hamdi","family":"Uyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9349-9530","authenticated-orcid":false,"given":"Mustafa Erkut","family":"\u00d6nder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammed \u0130kbal","family":"K\u0131l\u0131\u00e7","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,27]]},"reference":[{"issue":"26","key":"1138_CR1","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.2217\/fon-2021-0121","volume":"17","author":"M Aboueshia","year":"2021","unstructured":"Aboueshia M, Hussein MH, Attia AS, Swinford A, Miller P, Omar M et al (2021) Cancer and COVID-19: analysis of patient outcomes. Future Oncol 17(26):3499\u20133510. https:\/\/doi.org\/10.2217\/fon-2021-0121","journal-title":"Future Oncol"},{"issue":"1","key":"1138_CR2","doi-asserted-by":"publisher","first-page":"98","DOI":"10.2991\/jegh.k.200928.001","volume":"11","author":"A Alharthy","year":"2021","unstructured":"Alharthy A, Aletreby W, Faqihi F, Balhamar A, Alaklobi F, Alanezi K et al (2021) Clinical characteristics and predictors of 28-day mortality in 352 critically Ill patients with COVID-19: a retrospective study. J Epidemiol Glob Health 11(1):98\u2013104. https:\/\/doi.org\/10.2991\/jegh.k.200928.001","journal-title":"J Epidemiol Glob Health"},{"issue":"6","key":"1138_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2223","volume":"31","author":"M Alwani","year":"2021","unstructured":"Alwani M, Yassin A, Al-Zoubi RM, Aboumarzouk OM, Nettleship J, Kelly D et al (2021) Sex-based differences in severity and mortality in COVID-19. Rev Med Virol 31(6):e2223. https:\/\/doi.org\/10.1002\/rmv.2223","journal-title":"Rev Med Virol"},{"issue":"5","key":"1138_CR4","doi-asserted-by":"publisher","first-page":"30","DOI":"10.55563\/clinexprheumatol\/815tdt","volume":"39","author":"N Atas","year":"2021","unstructured":"Atas N, Eroglu GA, Sodan HN, Ozturk BO, Babaoglu H, Satis H et al (2021) Long-term safety and efficacy of anakinra and canakinumab in patients with familial Mediterranean fever: a single-centre real-life study with 101 patients. Clin Exp Rheumatol 39(5):30\u201336. https:\/\/doi.org\/10.55563\/clinexprheumatol\/815tdt","journal-title":"Clin Exp Rheumatol"},{"key":"1138_CR5","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.ijid.2020.11.149","volume":"103","author":"A Balkhair","year":"2021","unstructured":"Balkhair A, Al-Zakwani I, Al Busaidi M, Al-Khirbash A, Al Mubaihsi S, BaTaher H et al (2021) Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: Results of a prospective, open-label, interventional study. Int J Infect Dis 103:288\u2013296. https:\/\/doi.org\/10.1016\/j.ijid.2020.11.149","journal-title":"Int J Infect Dis"},{"issue":"11","key":"1138_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28581","volume":"67","author":"S Bami","year":"2020","unstructured":"Bami S, Vagrecha A, Soberman D, Badawi M, Cannone D, Lipton JM et al (2020) The use of anakinra in the treatment of secondary hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 67(11):e28581. https:\/\/doi.org\/10.1002\/pbc.28581","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"1138_CR7","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.jaci.2020.11.006","volume":"147","author":"G Bozzi","year":"2021","unstructured":"Bozzi G, Mangioni D, Minoia F, Aliberti S, Grasselli G, Barbetta L et al (2021) Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: an observational cohort study. J Allergy Clin Immunol 147(2):561-566.e564. https:\/\/doi.org\/10.1016\/j.jaci.2020.11.006","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"1138_CR8","doi-asserted-by":"publisher","first-page":"e325","DOI":"10.1016\/s2665-9913(20)30127-2","volume":"2","author":"G Cavalli","year":"2020","unstructured":"Cavalli G, De Luca G, Campochiaro C, Della-Torre E, Ripa M, Canetti D et al (2020) Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol 2(6):e325\u2013e331. https:\/\/doi.org\/10.1016\/s2665-9913(20)30127-2","journal-title":"Lancet Rheumatol"},{"issue":"4","key":"1138_CR9","doi-asserted-by":"publisher","first-page":"e253","DOI":"10.1016\/s2665-9913(21)00012-6","volume":"3","author":"G Cavalli","year":"2021","unstructured":"Cavalli G, Larcher A, Tomelleri A, Campochiaro C, Della-Torre E, De Luca G et al (2021) Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study. Lancet Rheumatol 3(4):e253\u2013e261. https:\/\/doi.org\/10.1016\/s2665-9913(21)00012-6","journal-title":"Lancet Rheumatol"},{"key":"1138_CR10","unstructured":"COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines (2022) National Institutes of Health. Retrieved from https:\/\/www.covid19treatmentguidelines.nih.gov\/. Accessed 8 Aug 2022"},{"issue":"14","key":"1138_CR11","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1182\/blood-2010-07-273417","volume":"117","author":"CA Dinarello","year":"2011","unstructured":"Dinarello CA (2011) Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 117(14):3720\u20133732. https:\/\/doi.org\/10.1182\/blood-2010-07-273417","journal-title":"Blood"},{"issue":"1","key":"1138_CR100","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1177\/0016986210390635","volume":"55","author":"X Fan","year":"2011","unstructured":"Fan X, Nowell DL (2011) Using propensity score matching in educational research. Gift Child Q 55(1):74\u201379. https:\/\/doi.org\/10.1177\/0016986210390635","journal-title":"Gift Child Q"},{"issue":"6","key":"1138_CR12","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1111\/ijlh.13309","volume":"42","author":"J Feld","year":"2020","unstructured":"Feld J, Tremblay D, Thibaud S, Kessler A, Naymagon L (2020) Ferritin levels in patients with COVID-19: a poor predictor of mortality and hemophagocytic lymphohistiocytosis. Int J Lab Hematol 42(6):773\u2013779. https:\/\/doi.org\/10.1111\/ijlh.13309","journal-title":"Int J Lab Hematol"},{"issue":"4","key":"1138_CR13","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/nrrheum.2010.4","volume":"6","author":"C Gabay","year":"2010","unstructured":"Gabay C, Lamacchia C, Palmer G (2010) IL-1 pathways in inflammation and human diseases. Nat Rev Rheumatol 6(4):232\u2013241. https:\/\/doi.org\/10.1038\/nrrheum.2010.4","journal-title":"Nat Rev Rheumatol"},{"issue":"7","key":"1138_CR14","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.autrev.2017.05.010","volume":"16","author":"PE Gavand","year":"2017","unstructured":"Gavand PE, Serio I, Arnaud L, Costedoat-Chalumeau N, Carvelli J, Dossier A et al (2017) Clinical spectrum and therapeutic management of systemic lupus erythematosus-associated macrophage activation syndrome: a study of 103 episodes in 89 adult patients. Autoimmun Rev 16(7):743\u2013749. https:\/\/doi.org\/10.1016\/j.autrev.2017.05.010","journal-title":"Autoimmun Rev"},{"issue":"6","key":"1138_CR15","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","volume":"24","author":"T Giavridis","year":"2018","unstructured":"Giavridis T, van der Stegen SJC, Eyquem J, Hamieh M, Piersigilli A, Sadelain M (2018) CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med 24(6):731\u2013738. https:\/\/doi.org\/10.1038\/s41591-018-0041-7","journal-title":"Nat Med"},{"issue":"4","key":"1138_CR16","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s00296-019-04393-7","volume":"40","author":"M Gilboa","year":"2020","unstructured":"Gilboa M, Bornstein G, Ben-Zvi I, Grossman C (2020) Macrophage activation syndrome complicating rheumatic diseases in adults: case-based review. Rheumatol Int 40(4):663\u2013669. https:\/\/doi.org\/10.1007\/s00296-019-04393-7","journal-title":"Rheumatol Int"},{"issue":"5","key":"1138_CR17","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrrheum.2015.179","volume":"12","author":"AA Grom","year":"2016","unstructured":"Grom AA, Horne A, De Benedetti F (2016) Macrophage activation syndrome in the era of biologic therapy. Nat Rev Rheumatol 12(5):259\u2013268. https:\/\/doi.org\/10.1038\/nrrheum.2015.179","journal-title":"Nat Rev Rheumatol"},{"issue":"12","key":"1138_CR18","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1002\/ajh.25982","volume":"95","author":"TC Hanff","year":"2020","unstructured":"Hanff TC, Mohareb AM, Giri J, Cohen JB, Chirinos JA (2020) Thrombosis in COVID-19. Am J Hematol 95(12):1578\u20131589. https:\/\/doi.org\/10.1002\/ajh.25982","journal-title":"Am J Hematol"},{"key":"1138_CR19","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.2147\/dddt.S73428","volume":"8","author":"D Hong","year":"2014","unstructured":"Hong D, Yang Z, Han S, Liang X, Ma K, Zhang X (2014) Interleukin 1 inhibition with anakinra in adult-onset still disease: a meta-analysis of its efficacy and safety. Drug Des Devel Ther 8:2345\u20132357. https:\/\/doi.org\/10.2147\/dddt.S73428","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"1138_CR20","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/jmv.26232","volume":"93","author":"B Hu","year":"2021","unstructured":"Hu B, Huang S, Yin L (2021) The cytokine storm and COVID-19. J Med Virol 93(1):250\u2013256. https:\/\/doi.org\/10.1002\/jmv.26232","journal-title":"J Med Virol"},{"issue":"3","key":"1138_CR21","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1159\/000519090","volume":"14","author":"E Karakike","year":"2022","unstructured":"Karakike E, Dalekos GN, Koutsodimitropoulos I, Saridaki M, Pourzitaki C, Papathanakos G et al (2022) ESCAPE: an open-label trial of personalized immunotherapy in critically lll COVID-19 patients. J Innate Immun 14(3):218\u2013228. https:\/\/doi.org\/10.1159\/000519090","journal-title":"J Innate Immun"},{"issue":"10","key":"1138_CR22","doi-asserted-by":"publisher","first-page":"e690","DOI":"10.1016\/s2665-9913(21)00216-2","volume":"3","author":"E Kyriazopoulou","year":"2021","unstructured":"Kyriazopoulou E, Huet T, Cavalli G, Gori A, Kyprianou M, Pickkers P et al (2021) Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis. Lancet Rheumatol 3(10):e690\u2013e697. https:\/\/doi.org\/10.1016\/s2665-9913(21)00216-2","journal-title":"Lancet Rheumatol"},{"issue":"3","key":"1138_CR23","doi-asserted-by":"publisher","first-page":"105924","DOI":"10.1016\/j.ijantimicag.2020.105924","volume":"55","author":"CC Lai","year":"2020","unstructured":"Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR (2020) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents 55(3):105924. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105924","journal-title":"Int J Antimicrob Agents"},{"key":"1138_CR24","doi-asserted-by":"publisher","first-page":"570251","DOI":"10.3389\/fimmu.2020.570251","volume":"11","author":"A L\u00f3pez-Reyes","year":"2020","unstructured":"L\u00f3pez-Reyes A, Martinez-Armenta C, Espinosa-Vel\u00e1zquez R, V\u00e1zquez-C\u00e1rdenas P, Cruz-Ramos M, Palacios-Gonzalez B et al (2020) NLRP3 inflammasome: the stormy link between obesity and COVID-19. Front Immunol 11:570251. https:\/\/doi.org\/10.3389\/fimmu.2020.570251","journal-title":"Front Immunol"},{"issue":"6","key":"1138_CR25","doi-asserted-by":"publisher","first-page":"e358","DOI":"10.1016\/s2665-9913(20)30096-5","volume":"2","author":"P Mehta","year":"2020","unstructured":"Mehta P, Cron RQ, Hartwell J, Manson JJ, Tattersall RS (2020) Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome. Lancet Rheumatol 2(6):e358\u2013e367. https:\/\/doi.org\/10.1016\/s2665-9913(20)30096-5","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"1138_CR26","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.hrtlng.2020.10.013","volume":"50","author":"SA \u00d1amendys-Silva","year":"2021","unstructured":"\u00d1amendys-Silva SA, Alvarado-\u00c1vila PE, Dom\u00ednguez-Cherit G, Rivero-Sigarroa E, S\u00e1nchez-Hurtado LA, Guti\u00e9rrez-Villase\u00f1or A et al (2021) Outcomes of patients with COVID-19 in the intensive care unit in Mexico: a multicenter observational study. Heart Lung 50(1):28\u201332. https:\/\/doi.org\/10.1016\/j.hrtlng.2020.10.013","journal-title":"Heart Lung"},{"issue":"2","key":"1138_CR27","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/art.30128","volume":"63","author":"PA Nigrovic","year":"2011","unstructured":"Nigrovic PA, Mannion M, Prince FH, Zeft A, Rabinovich CE, van Rossum MA et al (2011) Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum 63(2):545\u2013555. https:\/\/doi.org\/10.1002\/art.30128","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1138_CR28","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12969-021-00585-3","volume":"19","author":"O Phadke","year":"2021","unstructured":"Phadke O, Rouster-Stevens K, Giannopoulos H, Chandrakasan S, Prahalad S (2021) Intravenous administration of anakinra in children with macrophage activation syndrome. Pediatr Rheumatol Online J 19(1):98. https:\/\/doi.org\/10.1186\/s12969-021-00585-3","journal-title":"Pediatr Rheumatol Online J"},{"issue":"8","key":"1138_CR29","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1002\/art.41699","volume":"73","author":"KG Saag","year":"2021","unstructured":"Saag KG, Khanna PP, Keenan RT, Ohlman S, Osterling Koskinen L, Sparve E et al (2021) A randomized, phase II study evaluating the efficacy and safety of anakinra in the treatment of gout flares. Arthritis Rheumatol 73(8):1533\u20131542. https:\/\/doi.org\/10.1002\/art.41699","journal-title":"Arthritis Rheumatol"},{"key":"1138_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.virol.2020.08.011","volume":"551","author":"E Seyed Hosseini","year":"2020","unstructured":"Seyed Hosseini E, Riahi Kashani N, Nikzad H, Azadbakht J, Hassani Bafrani H, Haddad Kashani H (2020) The novel coronavirus disease-2019 (COVID-19): mechanism of action, detection and recent therapeutic strategies. Virology 551:1\u20139. https:\/\/doi.org\/10.1016\/j.virol.2020.08.011","journal-title":"Virology"},{"key":"1138_CR31","doi-asserted-by":"publisher","first-page":"570993","DOI":"10.3389\/fimmu.2020.570993","volume":"11","author":"L Tang","year":"2020","unstructured":"Tang L, Yin Z, Hu Y, Mei H (2020) Controlling cytokine storm is vital in COVID-19. Front Immunol 11:570993. https:\/\/doi.org\/10.3389\/fimmu.2020.570993","journal-title":"Front Immunol"},{"issue":"7","key":"1138_CR32","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1002\/ajh.25829","volume":"95","author":"E Terpos","year":"2020","unstructured":"Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN, Politou M et al (2020) Hematological findings and complications of COVID-19. Am J Hematol 95(7):834\u2013847. https:\/\/doi.org\/10.1002\/ajh.25829","journal-title":"Am J Hematol"},{"issue":"11","key":"1138_CR33","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/s41577-021-00588-x","volume":"21","author":"SM Vora","year":"2021","unstructured":"Vora SM, Lieberman J, Wu H (2021) Inflammasome activation at the crux of severe COVID-19. Nat Rev Immunol 21(11):694\u2013703. https:\/\/doi.org\/10.1038\/s41577-021-00588-x","journal-title":"Nat Rev Immunol"},{"issue":"12","key":"1138_CR34","doi-asserted-by":"publisher","first-page":"e754","DOI":"10.1016\/S2665-9913(20)30343-X","volume":"2","author":"BJ Webb","year":"2020","unstructured":"Webb BJ, Peltan ID, Jensen P, Hoda D, Hunter B, Silver A et al (2020) Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study. Lancet Rheumatol 2(12):e754\u2013e763. https:\/\/doi.org\/10.1016\/S2665-9913(20)30343-X","journal-title":"Lancet Rheumatol"},{"key":"1138_CR35","volume-title":"Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected","author":"WHO","year":"2020","unstructured":"WHO (2020) Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. WHO, Geneva"},{"issue":"1","key":"1138_CR36","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/jpen.1953","volume":"45","author":"X Zhao","year":"2021","unstructured":"Zhao X, Li Y, Ge Y, Shi Y, Lv P, Zhang J et al (2021) Evaluation of nutrition risk and its association with mortality risk in severely and critically ill COVID-19 patients. JPEN J Parenter Enteral Nutr 45(1):32\u201342. https:\/\/doi.org\/10.1002\/jpen.1953","journal-title":"JPEN J Parenter Enteral Nutr"},{"issue":"1","key":"1138_CR37","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s12519-019-00256-0","volume":"16","author":"LX Zou","year":"2020","unstructured":"Zou LX, Zhu Y, Sun L, Ma HH, Yang SR, Zeng HS et al (2020) Clinical and laboratory features, treatment, and outcomes of macrophage activation syndrome in 80 children: a multi-center study in China. World J Pediatr 16(1):89\u201398. https:\/\/doi.org\/10.1007\/s12519-019-00256-0","journal-title":"World J Pediatr"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-023-01138-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-023-01138-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-023-01138-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T05:26:14Z","timestamp":1682573174000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-023-01138-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,27]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["1138"],"URL":"https:\/\/doi.org\/10.1007\/s10787-023-01138-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1885399\/v1","asserted-by":"object"}]},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,27]]},"assertion":[{"value":"22 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest and also financial relationships.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Local ethics committee approval and participant consent were obtained for this study (date and number: 24.02.2022 and 2022\/04-09).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}